IDEAYA Biosciences Inc
IDYA24.440USD
-0.280-1.13%
Cierre 09/17, 16:00（ET）Cotizaciones retrasadas 15 min
2.14BCap. mercado
PérdidaP/E TTM
Más Datos de IDEAYA Biosciences Inc Compañía
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Información de la empresa
Símbolo de cotizaciónIDYA
Nombre de la empresaIDEAYA Biosciences Inc
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoMr. Yujiro S. Hata
Número de empleados131
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 23
Dirección7000 Shoreline Ct, Suite 350
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono16504436209
Sitio Webhttps://www.ideayabio.com/
Símbolo de cotizaciónIDYA
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoMr. Yujiro S. Hata
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Por negocioUSD
Nombre
Ganancia
Proporción
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
7.00M
100.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Estadísticas de accionistas
Actualizado: dom., 31 de ago
Actualizado: dom., 31 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
7.61%
Capital Research Global Investors
7.48%
Janus Henderson Investors
7.08%
Point72 Asset Management, L.P.
5.74%
Otro
57.10%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
7.61%
Capital Research Global Investors
7.48%
Janus Henderson Investors
7.08%
Point72 Asset Management, L.P.
5.74%
Otro
57.10%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
48.89%
Investment Advisor/Hedge Fund
31.84%
Hedge Fund
20.79%
Venture Capital
6.27%
Research Firm
4.17%
Individual Investor
0.90%
Pension Fund
0.82%
Bank and Trust
0.35%
Private Equity
0.16%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
2023Q1
290
47.36M
97.90%
-6.95M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
13.13M
14.99%
+167.11K
+1.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.15M
8.17%
+286.75K
+4.18%
Mar 31, 2025
Capital Research Global Investors
2.73M
3.12%
+169.03K
+6.59%
Mar 31, 2025
Janus Henderson Investors
6.40M
7.31%
+544.14K
+9.29%
Mar 31, 2025
Point72 Asset Management, L.P.
4.41M
5.04%
+4.27M
+3048.93%
Jun 06, 2025
The Vanguard Group, Inc.
5.08M
5.8%
+14.54K
+0.29%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
4.77M
5.44%
-295.60K
-5.84%
Mar 31, 2025
Deerfield Management Company, L.P.
3.27M
3.73%
+531.55K
+19.43%
Mar 31, 2025
State Street Global Advisors (US)
3.45M
3.93%
+125.33K
+3.77%
Mar 31, 2025
Logos Global Management LP
3.50M
4%
+500.00K
+16.67%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
Tema Oncology ETF
2.26%
ALPS Medical Breakthroughs ETF
1.33%
SPDR S&P Biotech ETF
0.69%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
iShares Biotechnology ETF
0.19%
Avantis US Small Cap Equity ETF
0.18%
iShares Russell 2000 Value ETF
0.16%
Global X Russell 2000 ETF
0.08%
iShares Russell 2000 ETF
0.07%
Schwab U.S. Small-Cap ETF
0.06%
Ver más
Tema Oncology ETF
Proporción2.26%
ALPS Medical Breakthroughs ETF
Proporción1.33%
SPDR S&P Biotech ETF
Proporción0.69%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.39%
iShares Biotechnology ETF
Proporción0.19%
Avantis US Small Cap Equity ETF
Proporción0.18%
iShares Russell 2000 Value ETF
Proporción0.16%
Global X Russell 2000 ETF
Proporción0.08%
iShares Russell 2000 ETF
Proporción0.07%
Schwab U.S. Small-Cap ETF
Proporción0.06%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
